Genzyme spinoffs?
This article was originally published in The Gray Sheet
Executive Summary
Firm announces plans to pursue "strategic alternatives" for its genetic testing, diagnostic products and pharmaceutical intermediates businesses. Management is exploring divestiture, spin-out or management buyout, Genzyme disclosed on May 6. Genzyme will also initiate a $2 billion stock buyback. The initiatives are designed to increase shareholder value, CEO Henri Termeer told analysts
You may also be interested in...
Genzyme's Genetic Testing Business Attracts $925 Million From LabCorp
Genzyme's marginally profitable genetic testing service business is being sold to Laboratory Corporation of America for $925 million, the firms announced Sept. 13
Sanofi-Aventis' Interest In Genzyme May Include Diagnostics Arm
Drug maker Sanofi-Aventis is signaling potential interest in Genzyme's molecular diagnostics business, suggesting that the unit could be retained if Sanofi succeeds in its quest to acquire Genzyme
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.